Terns Pharmaceuticals TERN
$ 5.73
2.23%
Quarterly report 2024-Q3
added 11-12-2024
Terns Pharmaceuticals Balance Sheet 2011-2024 | TERN
Annual Balance Sheet Terns Pharmaceuticals
2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-142 M | - | -62 M | -12.3 M | -82.5 M | - | - | - | - | - | - | - | |
Long Term Debt |
- | 544 K | - | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
603 K | 661 K | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | 877 K | 14.7 M | 14.5 M | - | - | - | - | - | - | - |
Total Current Liabilities |
11.9 M | 8.47 M | 6.82 M | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
13.2 M | 10.1 M | 7.77 M | 23.7 M | 19.7 M | 16.8 M | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | 836 K | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-333 M | -242 M | -182 M | -132 M | -91.9 M | -23.3 M | - | - | - | - | - | - | - |
Total Assets |
269 M | 287 M | 168 M | 92.3 M | 23.9 M | 89.1 M | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
79.9 M | 143 M | 47.7 M | - | - | - | - | - | - | - | - | - | - |
Book Value |
255 M | 277 M | 160 M | 68.6 M | 4.21 M | 72.2 M | - | - | - | - | - | - | - |
Total Shareholders Equity |
255 M | 277 M | 160 M | -117 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Terns Pharmaceuticals
2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
1.03 M | - | - | - | 63 K | 223 K | 386 K | 544 K | 702 K | 851 K | 1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
13.8 M | 12.2 M | 10 M | 13.2 M | 13.3 M | 15.5 M | 13.6 M | 10.1 M | 8.89 M | 7.64 M | 7.95 M | 7.77 M | 7.73 M | 6.68 M | 9.24 M | 23.7 M | 23.7 M | 23.7 M | 23.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-400 M | -378 M | -355 M | -333 M | -312 M | -282 M | -264 M | -242 M | -227 M | -210 M | -196 M | -182 M | -168 M | -156 M | -145 M | -132 M | -132 M | -132 M | -132 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
378 M | 231 M | 247 M | 269 M | 272 M | 290 M | 301 M | 287 M | 193 M | 145 M | 157 M | 168 M | 180 M | 188 M | 199 M | 92.3 M | 92.3 M | 92.3 M | 92.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
270 M | 91.5 M | 65.1 M | 79.9 M | 37.9 M | 80.9 M | 184 M | 143 M | 63 M | 16.8 M | 43.9 M | 47.7 M | 64.8 M | 67.6 M | 98.8 M | 74.9 M | 74.9 M | 74.9 M | 74.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
364 M | 219 M | 237 M | 255 M | 258 M | 274 M | 288 M | 277 M | 184 M | 137 M | 149 M | 160 M | 172 M | 181 M | 190 M | 68.6 M | 68.6 M | 68.6 M | 68.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
364 M | 219 M | 237 M | 255 M | 258 M | 274 M | 288 M | 277 M | 184 M | 137 M | 149 M | 160 M | 172 M | 181 M | 190 M | -117 M | -117 M | -117 M | -117 M | -90.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency